MGX

Metagenomi TherapeuticsF

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

Current thesis

Composite grade F from latest DB weights. Momentum 20.6 / Value 57.0

Posture

Defensive

Lead driver

Value

What changed

Value remains the lead driver in the composite, 7D delta +0.2.

What can break

Mixed signals. Wait for cleaner trend confirmation.

Momentum

Value

Sentiment

N/A

Setup hits (3d)

0 · Net Neutral

AI TargetsBase - · Bull - · Bear -

Data freshness

Prices

As of 2026-06-02

Fundamentals

As of 2026-06-02 • Vendor: Data Vendor v1

Scores

As of 2026-06-02 • Model: HYBRID_IC_RP

AI Memo

Unavailable: No memo yet

Investment thesis

As of 2026-06-02

Supporting evidence

What

Grade F · Defensive

Confidence Medium · Net Neutral

Target $9.33

Why

Momentum21 · Δ7d -

Value57 · Δ7d +0.2

SentimentN/A · Δ7d -

So what

Weak posture (Net Neutral). Prioritize risk control and patience.

Lead driver: Value · See fundamentals

Momentum

52% active weight

Current posture

7d trendTrend unavailable

Trend unavailable

Δ7d

Δ21d

Value

48% active weight

Current posture

7d trendFlat

Δ7d

+0.2

Δ21d

+0.3

Sentiment

N/A

Coverage pending

No current score

7d trendTrend unavailable

Trend unavailable

Δ7d

Δ21d

Why this grade

Composite grade F. Momentum 20.6 / Value 57.0

Fundamentals (TTM)

As of 2026-06-02

Market Cap

$50.07M

Beta

Shares Out

37.55M

P/E (TTM) · Derived

-0.6

P/S (TTM)

2.08

P/FCF (TTM) · Derived

-0.54

Rev YoY

-24.8%

EPS YoY

-6.9%

Gross Margin

Op Margin

-298.5%

Net Debt

Current Ratio

6.42

As of 2026-06-02 • Updated nightlySource: Internal modelMethodology